A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions

NCT06890286 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: BR3006
DRUG: BR3006A
DRUG: BR3006B
DRUG: BR3006C

Sponsor

Boryung Pharmaceutical Co., Ltd